The issue of macular retinal degeneration is one of the key areas of ophthalmology. Recent advances in the targeted delivery of vascular endothelial growth factor (VEGF) suppressants have significantly impacted the patient's prognosis in the form of a significant deceleration in disease progression. Some of the drugs have gradually found their use in other indications (central retinal vein occlusion or diabetic macular edema). The following text gives a brief look at the physiology of VEGF, but not only in the eye, but throughout the human body, particularly in the context of adverse effects resulting from systemic inhibition of its effects.
- VEGF: A Key Player not Only in Macular Degeneration. A Review
- Results of 15 Years of Collaboration between the Departments of Ophthalmology and Stomatology in Oncological Surgery of the Orbit: A Diagnostic and Therapeutic Approach
- Usage of Digital D Chart Test as a Modification of Amsler Grid in Ophthalmology and Optometry
- Ocular Complications of Diabetes Mellitus in Pregnancy – Case Report
- Acute Elevation of Intraocular Pressure in Patient with Hyperlipidemic Myeloma
- Recommendations for the Management of Uveitis Associated with Juvenile Idiopathic Arthritis: The Czech and Slovak Adaptation of the Share Initiative